Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Complete Protein

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,105 result(s) found for: Complete Protein. Displaying page 1 of 56.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-000333-13 Sponsor Protocol Number: APHP200046 Start Date*: Information not available in EudraCT
    Sponsor Name:APHP DRCI
    Full Title: Efficacy of the nonavalent HPV vaccine in the treatment of difficult-to-treat palmo-plantar warts
    Medical condition: Vaccination by nonavalent vaccine against HPV could lead to a complete resolution of difficult-to-treat palmo-plantar warts in patients of more than 15 years and 3 months of age
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000108-42 Sponsor Protocol Number: V505-001 Start Date*: 2017-01-27
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase IIa Randomized, Double-Blinded, Controlled With GARDASIL™ Clinical Trial to Study the Tolerability and Immunogenicity of V505 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like-Particl...
    Medical condition: vaccination against HPV infection/related disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004865 10071147 Human papilloma virus immunization LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-006579-41 Sponsor Protocol Number: ANG3070-CKD-201 Start Date*: 2022-03-07
    Sponsor Name:Angion Biomedica Corp.
    Full Title: A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of Safety and Efficacy Of ANG-3070 in Patients with Primary Glomerular Disease and Persistent Proteinuria
    Medical condition: Primary glomerular disease and persistent proteinuria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10037032 Proteinuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005093-38 Sponsor Protocol Number: V503-004 Start Date*: 2016-07-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck Co., Inc
    Full Title: An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27-...
    Medical condition: Prevention of cervical,vulvar,vaginal, and anal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by HPV Types 6,11,16,18,31,33,45,52,58
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061331 Papilloma viral infection PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed) FI (Completed) AT (Completed) ES (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003591-13 Sponsor Protocol Number: V503-076 Start Date*: 2024-05-06
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Conco...
    Medical condition: Papilloma viral infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2006-001865-41 Sponsor Protocol Number: CC-5013-MM-015 Start Date*: 2007-03-27
    Sponsor Name:Celgene International Sàrl
    Full Title: A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and ...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) FR (Completed) DE (Completed) IE (Completed) CZ (Completed) AT (Completed) GB (Completed) DK (Completed) SE (Completed) IT (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-004823-39 Sponsor Protocol Number: CC-5013-MM-020/IFM 07-01 Start Date*: 2008-04-03
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, 3-ARM STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) PLUS LOW-DOSE DEXAMETHASONE WHEN GIVEN UNTIL PROGRESSIVE DISEASE OR FOR 18 FOUR-WEEK...
    Medical condition: Previously untreated multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) IE (Prematurely Ended) IT (Completed) AT (Completed) ES (Completed) SE (Completed) BE (Completed) PT (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-023189-27 Sponsor Protocol Number: RG-10-179 Start Date*: 2011-01-20
    Sponsor Name:University of Birmingham
    Full Title: The pharmacogenetics of vitamin D response in tuberculosis
    Medical condition: Tuberculosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002023-15 Sponsor Protocol Number: EFC16293 Start Date*: 2020-02-25
    Sponsor Name:Bioverativ Therapeutics Inc. (a Sanofi company)
    Full Title: Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTE...
    Medical condition: severe hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10016080 Factor VIII deficiency PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) FR (Ongoing) BG (Completed) BE (Completed) GR (Completed) HU (Completed) NL (Completed) ES (Completed) Outside EU/EEA IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-006950-30 Sponsor Protocol Number: CLOU064I12201 Start Date*: 2022-08-02
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A one month, investigator and participant blinded study to investigate the efficacy and safety of remibrutinib (LOU064) at multiple dose levels in adult participants with peanut allergy
    Medical condition: Allergy, Peanut
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-000838-36 Sponsor Protocol Number: PX104.1.7-201 Start Date*: 2004-09-20
    Sponsor Name:Pharmexa A/S
    Full Title: A Phase II trial evaluating the immunological and clinical efficay and safety of HER-2 Protein Autovac(TM) monotherapy in patients with metastatic breast cancer
    Medical condition: Female patients with histologically proven metastatic or locally advanced breast cancer who have HER-2 overexpression in the primary tumour and/or a metastatic lesion.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006773-32 Sponsor Protocol Number: HPV_CSP01 Start Date*: 2009-05-20
    Sponsor Name:Health Protection Agency
    Full Title: A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines
    Medical condition: This study will investigate vaccines that prevent premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. This study will investigate wheth...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058580 Human papilloma virus serology test LLT
    Population Age: Adolescents, Under 18 Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004418-17 Sponsor Protocol Number: I-BCT-1 Start Date*: 2014-05-07
    Sponsor Name:Oslo University Hospital
    Full Title: Improved breast cancer therapy (I-BCT-1) in the neoadjuvant and metastatic setting: A phase 2 clinical trial protocol studying biological rationale for the optimal selection of treatment regimens.
    Medical condition: breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023603-10 Sponsor Protocol Number: S52762 Start Date*: 2011-01-18
    Sponsor Name:UZ Leuven
    Full Title: Ilaris (Canakinumab) in the Schnitzler syndrome
    Medical condition: Schnitzler syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.1 10062908 Schnitzler's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002451-15 Sponsor Protocol Number: V102_15 Start Date*: 2014-09-19
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of GSK Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to GSK...
    Medical condition: The current study is designed to assess immunological non-inferiority of the MenABCWY vaccine, administered according to 0, 2 month schedule to healthy adolescents 10 to 18 years of age, to those o...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10027202 Meningitis bacterial PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-003022-32 Sponsor Protocol Number: CL012_140 Start Date*: 2019-10-12
    Sponsor Name:ChemoCentryx, Inc.
    Full Title: An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome
    Medical condition: Primary Focal Segmental Glomerulosclerosis (FSGS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002112-99 Sponsor Protocol Number: F1K-MC-EVDK Start Date*: 2006-09-26
    Sponsor Name:Eli Lilly & Company Limited
    Full Title: A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction
    Medical condition: severe sepsis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040047 Sepsis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) SE (Prematurely Ended) FR (Completed) FI (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-003364-51 Sponsor Protocol Number: AUR-VCS-2012-01 Start Date*: 2014-10-24
    Sponsor Name:Aurinia Pharmaceuticals Inc.
    Full Title: A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) with Placebo in Achieving Remission in Patients with Active Lupus Nephritis
    Medical condition: Active lupus nephritis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005339-56 Sponsor Protocol Number: CQGE031G12301 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma AG
    Full Title: A 52 week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients wi...
    Medical condition: Allergy, Peanut
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Ongoing) DE (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021166-30 Sponsor Protocol Number: 2010-SS-Canakinumab Start Date*: 2010-11-25
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Efficacy and safety of canakinumab in Schnitzler syndrome
    Medical condition: Schnitzler syndrome is an acquired autoinflammatory syndrome characterized by urticaria and monoclonal gammopathy, accompanied by intermittent fever, arthralgia or arthritis, bone pain and lymphade...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:03:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA